ECSP056014A - MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA - Google Patents

MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA

Info

Publication number
ECSP056014A
ECSP056014A EC2005006014A ECSP056014A ECSP056014A EC SP056014 A ECSP056014 A EC SP056014A EC 2005006014 A EC2005006014 A EC 2005006014A EC SP056014 A ECSP056014 A EC SP056014A EC SP056014 A ECSP056014 A EC SP056014A
Authority
EC
Ecuador
Prior art keywords
specificity
human
antibody molecules
antibody molecule
producing
Prior art date
Application number
EC2005006014A
Other languages
English (en)
Inventor
Alastair David Griffiths Lawson
Andrew George Popplewell
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of ECSP056014A publication Critical patent/ECSP056014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La invención se refiere a una molécula de anticuerpo que tiene especificidad para determinantes antigénicos de IL-1ß, usos terapéuticos de la molécula de anticuerpo y métodos para producir dicha molécula de anticuerpo.
EC2005006014A 2003-02-13 2005-09-13 MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA ECSP056014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303337.0A GB0303337D0 (en) 2003-02-13 2003-02-13 Biological products

Publications (1)

Publication Number Publication Date
ECSP056014A true ECSP056014A (es) 2006-01-27

Family

ID=9952969

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006014A ECSP056014A (es) 2003-02-13 2005-09-13 MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA

Country Status (26)

Country Link
US (2) US7608694B2 (es)
EP (2) EP1597282B1 (es)
JP (2) JP4668896B2 (es)
KR (1) KR20050099509A (es)
CN (1) CN1745103A (es)
AR (1) AR043159A1 (es)
AT (1) ATE525397T1 (es)
AU (1) AU2004210776B2 (es)
BR (1) BRPI0407233A (es)
CA (1) CA2515474C (es)
CL (1) CL2004000259A1 (es)
CY (1) CY1112507T1 (es)
DK (1) DK1597282T3 (es)
EA (1) EA200501286A1 (es)
EC (1) ECSP056014A (es)
ES (1) ES2373953T3 (es)
GB (1) GB0303337D0 (es)
IS (1) IS8013A (es)
MX (1) MXPA05007392A (es)
NO (1) NO20054223L (es)
PE (1) PE20040947A1 (es)
PL (1) PL378412A1 (es)
PT (1) PT1597282E (es)
SI (1) SI1597282T1 (es)
TW (1) TW200505942A (es)
WO (1) WO2004072116A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP2399936A3 (en) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anti-CD154 antibodies
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
EP2163562B1 (en) 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
PL2848258T3 (pl) * 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
JP5183484B2 (ja) 2005-12-09 2013-04-17 ユセベ ファルマ ソシエテ アノニム ヒトｉｌ−６に対して特異性を有する抗体分子
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
EP2125894B1 (en) 2007-03-22 2018-12-19 Biogen MA Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
HRP20141194T1 (hr) 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
WO2009134805A2 (en) * 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
JP2012502059A (ja) 2008-09-05 2012-01-26 ゾーマ テクノロジー リミテッド ＩＬ−１β関連疾患を処置または予防するための方法
EP2398498B1 (en) 2009-02-17 2018-09-05 UCB Biopharma SPRL Antibody molecules having specificity for human ox40
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
IN2012DN02401A (es) 2009-09-24 2015-08-21 Ucb Pharma Sa
CN102655880A (zh) * 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
NZ603191A (en) 2010-05-07 2015-02-27 Xoma Technology Ltd Methods for the treatment of il-1b related conditions
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
PL2731973T3 (pl) 2011-07-13 2018-04-30 Ucb Biopharma Sprl Bakteryjny szczep gospodarz wykazujący ekspresję dsbc
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
DK2814843T3 (da) 2012-02-13 2020-06-22 Agency Science Tech & Res IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2014011955A2 (en) 2012-07-12 2014-01-16 Abbvie, Inc. Il-1 binding proteins
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
CN106163501B (zh) 2014-01-20 2019-05-31 厄弗翁简易股份公司 固态药物组合物的重构方法
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
US9560393B2 (en) * 2015-02-20 2017-01-31 Disney Enterprises, Inc. Media processing node
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
RU2754683C2 (ru) 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020093957A1 (zh) * 2018-11-07 2020-05-14 泽达生物医药有限公司 结合人IL-1β的抗体、其制备方法和用途
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
EP4255926A1 (en) 2020-12-07 2023-10-11 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
KR20230118128A (ko) 2020-12-07 2023-08-10 유씨비 바이오파마 에스알엘 인터루킨-22에 대한 항체
JP2024516305A (ja) 2021-05-03 2024-04-12 ユーシービー バイオファルマ エスアールエル 抗体
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN113855807A (zh) * 2021-10-25 2021-12-31 孙良丹 一种试剂在制备治疗/抑制银屑病药物中的应用
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB129105A (en) 1918-07-02 1919-07-02 Alfred George Hubble Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels.
EP0569687B1 (en) 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
AU703222B2 (en) 1995-01-23 1999-03-18 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
JPH09183799A (ja) * 1995-11-06 1997-07-15 Merck Patent Gmbh ヒト化モノクローナル抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
AU2002355249A1 (en) * 2001-07-26 2003-02-17 Eli Lilly And Company Interleukin-1 beta antibodies
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
ATE525397T1 (de) 2011-10-15
EP2287193A1 (en) 2011-02-23
PL378412A1 (pl) 2006-04-03
CA2515474C (en) 2013-11-12
JP2010246553A (ja) 2010-11-04
SI1597282T1 (sl) 2012-02-29
AU2004210776B2 (en) 2011-04-07
CN1745103A (zh) 2006-03-08
US20060228358A1 (en) 2006-10-12
US8465744B2 (en) 2013-06-18
EP1597282B1 (en) 2011-09-21
CL2004000259A1 (es) 2005-04-15
TW200505942A (en) 2005-02-16
MXPA05007392A (es) 2005-09-12
WO2004072116A3 (en) 2004-11-18
ES2373953T3 (es) 2012-02-10
KR20050099509A (ko) 2005-10-13
US20100158913A1 (en) 2010-06-24
EA200501286A1 (ru) 2006-02-24
DK1597282T3 (da) 2012-01-23
EP1597282A2 (en) 2005-11-23
NO20054223D0 (no) 2005-09-12
JP2007515925A (ja) 2007-06-21
IS8013A (is) 2005-09-07
AU2004210776A1 (en) 2004-08-26
CA2515474A1 (en) 2004-08-26
US7608694B2 (en) 2009-10-27
GB0303337D0 (en) 2003-03-19
CY1112507T1 (el) 2015-12-09
JP4668896B2 (ja) 2011-04-13
PT1597282E (pt) 2012-01-05
WO2004072116A2 (en) 2004-08-26
PE20040947A1 (es) 2004-12-29
BRPI0407233A (pt) 2006-01-31
AR043159A1 (es) 2005-07-20
NO20054223L (no) 2005-11-08

Similar Documents

Publication Publication Date Title
ECSP056014A (es) MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
ECSP088613A (es) Moléculas de anticuerpo que tienen especificidad para la il-6 humana
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
ECSP045470A (es) Productos biologicos
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
UY32489A (es) Moléculas de anticuerpos que tienen especificidad de unión por il-13 humana
BR112014011404A2 (pt) moléculas de anticorpos com especificidade para o ox40 humano
CY2016025I2 (el) Παραγοντες δημιουργιας ελαιογελης που περιεχουν τριτερπενια, ελαιογελη που περιεχει τριτερπενια και μεθοδος για την παραγωγη ελαιογελης που περιεχει τριτερπενια
ECSP066379A (es) Anticuerpos rg1 y usos de los mismos
CO2020005685A2 (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ECSP088508A (es) Antagonistas de neuropilina
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
AR060130A1 (es) Formulacion de un anticuerpo monoclonal humano anti- igf-1r
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
ITRM20040586A1 (it) Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
CL2022001684A1 (es) Anticuerpo con especificidad de unión para il-13 humana
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6
ECSP045099A (es) Productos biologicos
TH128473A (th) แอนติ-il-13 แอนติบอดี ที่ได้รับการจัดการ องค์ประกอบ วิธีและการใช้